ArticleJournal of translational medicine2025
LINC02888 promotes HGSOC progression and immune evasion via PPIB-mediated stabilization of LAPTM5 mRNA and inhibition of RIG-I-like receptor signaling.
Article in Journal of translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Article
- Cyclophilin A stabilizes the capsid protein p72 to facilitate African swine fever virus replication.Nature communications · 2026Article
- Identification of an m7G-Related lncRNA Signature for Prognostic Prediction and Immune Landscape Characterization in Early Gastric Cancer.OncoTargets and therapy · 2026Article
- LAPTM5 drives omental metastasis in high-grade serous ovarian cancer via TGF-β/Smad-mediated epithelial plasticity.Journal of translational medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundHigh-grade serous ovarian cancer (HGSOC) remains highly lethal due to late diagnosis and chemoresistance. Long noncoding RNAs (lncRNAs) have emerged as critical regulators of tumor progression. This study investigates the role of the cytoplasmic lncRNA LINC02888 in HGSOC.
methodsWe identified overexpression of LINC02888 in HGSOC tissues and cell lines through whole-transcriptome sequencing, qPCR, in situ hybridization, and analyses of TCGA/GTEx datasets. Functional assays including CCK-8, EdU, colony formation, wound healing, Transwell migration/invasion, and flow cytometry were performed after modulating LINC02888 expression. RNA pull-down coupled with mass spectrometry identified the RNA-binding protein PPIB as an interactor of LINC02888. RNA-seq following both LINC02888 and PPIB knockdown, along with Western blot, qPCR analyses and functional assays, revealed that LAPTM5 is a downstream effector. Furthermore, RIP-qPCR, deletion mapping, and ActD assays confirmed that LINC02888 binds PPIB, which stabilizes LAPTM5 mRNA via its 3'UTR. The effect on the RIG-I-like receptor pathway was evaluated by measuring the expression levels of RIG-I, IRF7, and ISG15. Finally, in vivo, the critical role of the LINC02888/PPIB/ LAPTM5 axis in ovarian tumor progression were explored by axillary subcutaneous injection of specifically transfected OVCAR3 cells into nude mice.
resultsLINC02888 was significantly upregulated in HGSOC tissues and correlated with advanced disease and poor prognosis. Silencing LINC02888 inhibited proliferation, migration, and invasion, while inducing apoptosis; conversely, overexpression promoted these oncogenic behaviors. Mechanistically, LINC02888 interacts with PPIB to stabilize LAPTM5 mRNA via its 3'UTR, resulting in elevated LAPTM5 protein levels and suppression of RIG-I-like receptor signaling. Rescue experiments confirmed the critical role of the LINC02888-PPIB-LAPTM5 axis in HGSOC progression in vivo and vitro.
conclusionsOur findings reveal that LINC02888 drives HGSOC progression through a mechanism involving PPIB-mediated stabilization of LAPTM5 mRNA, which suppresses RIG-I-like receptor signaling. It also appropriately suggests that inhibiting this innate immune pathway may contribute to an immunosuppressive tumor microenvironment, making the LINC02888-PPIB-LAPTM5 axis a promising therapeutic target for this aggressive malignancy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.